MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

In This Article:

By David Bautz, PhD

NASDAQ:MTVA

READ THE FULL MTVA RESEARCH REPORT

Business Update

NeuroBo Becomes MetaVia

On November 18, 2024, NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced a strategic realignment ahead of upcoming clinical milestones along with a corporate name change to MetaVia Inc. (NASDAQ:MTVA). The change went into effect on November 29, 2024. We are republishing the latest research report under the MTVA ticker.

Topline Results from Phase 2a Trial of DA-1241 in MASH Expected in December 2024

MetaVia Inc. is developing DA-1241 as a treatment for metabolic dysfunction-associated steatohepatitis (MASH; formerly NASH). DA-1241 is a novel chemical entity that selectively activates GPR119, stimulates the secretion of insulin and incretin hormones such as glucagon-like peptide-1 (GLP-1), reduces plasma glucose levels without causing hypoglycemia, and lowers plasma lipid levels of both triglycerides and cholesterol.

The current Phase 2a trial has two parts: Part 1 is examining DA-1241 as a monotherapy while Part 2 is examining DA-1241 in combination with sitagliptin. For Part 1, subjects were randomized in a 1:2:1 ratio into three treatment groups: DA-1241 50 mg, DA-1241 100 mg, or placebo. For Part 2, subjects were randomized in a 2:1 ratio into two treatment groups: DA-1241 100 mg/sitagliptin 100 mg or placebo. A total of 109 subjects were randomized into the study, with 95 subjects completing dosing. For both Part 1 and Part 2, the primary endpoint is the change from baseline in alanine aminotransferase (ALT) levels at Week 16. Secondary endpoints include the proportion of subjects with normalization of ALT, absolute change in total cholesterol, low and high-density lipoprotein cholesterol, triglycerides, and free fatty acids from baseline. We anticipate topline results from both Part 1 and Part 2 of the study in December 2024.

MAD Part 2 Results from Phase 1 Trial of DA-1726 Expected in 1Q25

In September 2024, MetaVia announced positive topline results for the single ascending dose (SAD) Part 1 of the ongoing Phase 1 clinical trial of DA-1726 for the treatment of obesity. A total of 45 obese but otherwise healthy individuals were randomized in a double blind, 6:3 ratio to receive DA-1726 or placebo. The results showed that DA-1726 was safe, well tolerated, and had linear pharmacokinetics (PK). In regards to safety, only five subjects in the DA-1726 group reported adverse events (AEs) compared to three subjects in the placebo group. Due to the strong safety profile, at least one additional dosing cohort is being added to evaluate the maximum tolerated dose.